FONAR Announces Results of the Third
Fiscal Quarter 2009 As Net Income Soars Past $1 Million for
Nine Month Period
MELVILLE,
NEW YORK, May 19, 2009 - FONAR Corporation (NASDAQ-FONR),
The Inventor of MR Scanning™, today announced its earnings
for the third quarter of fiscal 2009 ending March 31, 2009. Net
income for the nine month period ending March 31, 2009 was $1.1
million as compared to the nine month period one year earlier when
there was a net loss of $6.7 million. For the third fiscal quarter
ending March 31, 2009, the Company reported net income of $730,000
as compared to the same period one year earlier when it had a loss
of $2.7 million.
Revenues increased 7.0% to $29.3 million for the
nine month period ending March 31, 2009 as compared to $27.4
million for the nine month period ending March 31, 2008. For
the quarter ending March 31, 2009, revenues increased 39.5%
to $11.3 million as compared to $8.1 million for the quarter
ending March 31, 2008.
Raymond Damadian, M.D., president and chairman
of FONAR Corporation said, “We are delighted that the
Company has once again become profitable. In fact we now have
two straight quarters of income greater than $700,000. There
are several reasons for this. While 2008 was a difficult year,
we initiated an aggressive cost-cutting program. Costs and expenses
have been reduced in most categories but most significantly
in our selling, general and administrative expenses (S, G & A).
Overall, S, G & A was reduced 36.0% from $15.5 million for
the nine months ending March 31, 2008 to $10.0 million for the
most current nine month period.”
Dr. Damadian continued, “Another reason
is a refreshed focus on ‘selling scans’ through
our UPRIGHT® Multi-Position™ MRI managed sites. We
currently have nine UPRIGHT® MRIs and one older FONAR QUAD™ MRI
being managed by HMCA (Health Management Corporation of America),
FONAR’s wholly-owned subsidiary (www.hmca.com). There
are UPRIGHT® MRI centers that scan more than 500 patients
per month and we would like that to happen pervasively within
the HMCA network.”
“We often find that the busier UPRIGHT® Multi-Position
MRI centers are in an area with many single-position, recumbent-only
competitor MRIs around them,” continued Dr. Damadian. “They
will energize the local imaging market. When claustrophobic
patients find out about the UPRIGHT® MRI, they will demand
it from their referring physicians. Patients and the referring
physicians seeking spine care will also seek out the best diagnostic
device for their condition. Add advantages of scanning overweight
patients, patients who can’t lie down, weight-bearing
imaging of men and women with pelvic floor dysfunction, patients
with scoliosis and the ability to perform high quality routine
imaging of other body parts, and you have the opportunity for
a very busy MRI site.”
As of March 31, 2009, there were 133 FONAR UPRIGHT® Multi-Position™ MRI
units installed worldwide. During the third quarter of fiscal
2009 total product sales increased dramatically by 162.2 % to
$6.2 million from $2.3 million over the corresponding quarter
one year earlier.
During the third fiscal quarter of 2009, FONAR
announced it has sold two UPRIGHT® Multi-Position™ MRI
scanners to Doshi Diagnostic Imaging Services, P.C., which is
among the country’s largest privately held multi-modality
imaging companies, as well as the largest radiology group in
New York. Doshi Diagnostic is headquartered in Bethpage, Long
Island, and operates approximately 40 centers in Florida, New
Jersey, Long Island, and New York City.
Another sale of an UPRIGHT® Multi-Position™ MRI
was to the Tripoli Medical Center, a leading state-of-the-art
medical center in Libya with approximately 1450 beds, 1000 physicians,
and 3000 employees. This is an especially significant sale for
FONAR, because it marks the entrance of the company’s
UPRIGHT® imaging technology into the markets of Africa and
the Middle East.
Also during the third fiscal quarter of 2009 Raymond
Damadian, M.D. became the recipient of the 2009 AIMBE (American
Institute for Medical and Biological Engineering) Honorary Fellow
Award for his discovery of MRI. Dr. Damadian is the originator
of the concept of magnetic resonance (MR) scanning of the human
body (1969). The AIMBE Award was presented at the annual meeting
of AIMBE, held February 11-13 in Washington, D.C.
The award says: “In 1970, Raymond Damadian,
M.D., made the discovery that is the basis for magnetic resonance
(MR) scanning that there is a marked difference in relaxation
times between normal and abnormal tissues of the same type,
as well as between different types of normal tissues. This seminal
discovery, which remains the basis for the making of every MRI
image ever produced, is the foundation of the MRI industry.
Dr. Damadian published his discovery in his milestone 1971 paper
in the journal Science (Science 171:1151, 1971) and filed the
pioneer patent for the practical use of his discovery in 1972.” (www.fonar.com/news/022409.htm).
#
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED) |
ASSETS
|
March 31,
2009
(UNAUDITED) |
June 30,
2008 |
Current Assets:
Cash and cash equivalents
|
$ 1,605
|
$ 1,326 |
| Marketable securities |
18 |
1,068 |
| Accounts receivable - net |
5,206 |
4,689 |
| Accounts receivable - related parties - net |
619 |
469 |
| Medical receivables - net |
555 |
1,228 |
| Management fee receivable - net |
4,051 |
5,040 |
Management fee receivable - related medical
practices - net
|
1,480 |
1,372 |
Costs and estimated earnings in excess of billings on
uncompleted contracts
|
528 |
6 |
| Inventories |
3,793 |
3,256 |
Current portion of advances and notes to related medical
practices
|
193 |
214 |
Current portion of notes receivable less discount for
below market interest
|
509 |
2,508 |
| Prepaid expenses and other current assets |
409 |
811 |
Total Current Assets
|
18,966 |
21,987 |
| |
---------------- |
---------------- |
| Property and equipment - net |
3,152 |
3,933 |
| Advances and notes to related medical practices - net |
133 |
263 |
| Notes receivable less discount for below market interest |
1,912 |
2,297 |
| Other intangible assets - net |
4,896 |
4,810 |
| Other assets |
574 |
1,936 |
| |
---------------- |
---------------- |
Total Assets |
$ 29,633 |
$ 35,226 |
| |
=========== |
=========== |
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(000's OMITTED)
|
| LIABILITIES AND STOCKHOLDERS' DEFICIENCY |
March 31,
2009
(UNAUDITED) |
June 30,
2008 |
| Current Liabilities: |
|
|
Current portion of long-term debt and capital
leases
|
$ 141 |
$ 373 |
Accounts payable
|
3,720 |
4,020 |
Other current liabilities
|
8,045 |
8,316 |
Unearned revenue on service contracts
|
5,045 |
4,732 |
Unearned revenue on service contracts - related parties
|
612 |
462 |
Customer advances
|
7,871 |
12,804 |
Customer advances - related party
|
854 |
1,472 |
Billings in excess of costs and estimated earnings on
uncompleted contracts
|
5,133 |
5,773 |
Total Current Liabilities
|
31,421 |
37,952 |
| Long-Term Liabilities: |
|
|
Due to related medical practices
|
95 |
98 |
Long-term debt and capital leases, less current portion
|
746 |
757 |
Other liabilities
|
319 |
497 |
Total Long-Term Liabilities
|
1,160 |
1,352 |
Total Liabilities
|
32,581 |
39,304 |
| Minority interest |
64 |
167 |
| |
|
|
| STOCKHOLDERS' DEFICIENCY: |
|
|
Class A non-voting preferred stock $.0001 par value;
1,600,000 authorized, 313,451 issued and outstanding
at March 31, 2009 and June 30, 2008
|
- |
- |
Common Stock $.0001 par value; 30,000,000
shares
authorized at March 31, 2009 and June 30, 2008,
4,915,918 issued at March 31, 2009 and June 30, 2008
4,904,275 outstanding at March 31, 2009 and June 30, 2008
|
1 |
1 |
Class B Common Stock $ .0001 par
value; 800,000
shares authorized, (10 votes per share), 158 issued
and outstanding at March 31, 2009 and June 30, 2008
|
- |
- |
Class C Common Stock $.0001 par value; 2,000,000 shares
authorized, (25 votes per share), 382,513 issued
and outstanding at March 31, 2009 and June 30, 2008
|
- |
- |
Paid-in capital in excess of par value |
172,276 |
172,276 |
| Accumulated other comprehensive loss |
( 25) |
( 73) |
| Accumulated deficit |
(174,320) |
(175,380) |
| Notes receivable from employee stockholders |
( 269) |
( 394) |
Treasury stock, at cost - 11,643 shares of common stock
at March 31, 2009 and June 30, 2008
|
( 675) |
( 675) |
| |
---------------- |
---------------- |
Total Stockholders' Deficiency
|
( 3,012) |
(4,245) |
Total Liabilities and Stockholders' Deficiency
|
$ 29,633 |
$ 35,226 |
| |
=========== |
=========== |
FONAR CORPORATION
AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data)
|
| |
FOR THE THREE MONTHS ENDED
MARCH 31,
|
| REVENUES |
2009
|
2008
|
Product sales - net
|
$ 6,156
|
$2,348
|
Service and repair fees - net
|
2,291
|
2,515
|
Service and repair fees - related
parties - net
|
331
|
270
|
Management and other fees - net
|
1,736
|
2,110
|
Management and other fees - related
medical practices-net
|
742
|
828
|
| |
----------------
|
----------------
|
Total Revenues - Net
|
11,256
|
8,071
|
| |
----------------
|
----------------
|
| COSTS AND EXPENSES |
|
|
Costs related to product sales
|
3,325
|
2,237
|
Costs related to service and repair fees
|
865
|
1,148
|
Costs related to service and
repair fees - related parties
|
125
|
123
|
Costs related to management and other fees
|
1,039
|
1,342
|
Costs related to management and other fees
- related medical practices
|
686
|
751
|
Research and development
|
872
|
1,189
|
Selling, general and administrative
|
3,219
|
4,311
|
Provision (Credit) for bad debts
|
363
|
( 309)
|
|
----------------
|
----------------
|
Total Costs and Expenses
|
10,494
|
10,792
|
| |
----------------
|
----------------
|
| Income (Loss) From Operations |
762
|
( 2,721)
|
| |
|
|
| Interest Expense |
( 75)
|
( 105)
|
| Investment Income |
91
|
156
|
| Interest Income - Related Parties |
5
|
8
|
| Other (Expense) Income |
( 17)
|
1
|
| Minority Interest in Income of Partnerships |
-
|
( 34)
|
| Provision for Income Taxes |
( 36)
|
-
|
| |
----------------
|
----------------
|
| NET INCOME (LOSS) |
$ 730
|
$( 2,695)
|
| |
===========
|
===========
|
| Net Income (Loss) Available to Common Stockholders |
$ 686
|
$ (2,695)
|
| |
===========
|
===========
|
| Basic Net Income (Loss) Per Common Share |
$ 0.14
|
$ (0.55)
|
| |
===========
|
===========
|
| Diluted Net Income (Loss) Per Common Share |
$ 0.13
|
$ (0.55)
|
| |
===========
|
===========
|
| Basic and Diluted Income Per Share - Common
C |
$ 0.04
|
-
|
| |
===========
|
===========
|
| Weighted Average Basic Shares Outstanding |
4,904,275
|
4,904,261
|
| |
===========
|
===========
|
| Weighted Average Diluted Shares Outstanding |
5,031,779
|
4,904,261
|
| |
===========
|
===========
|
FONAR CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(000's OMITTED, except per share data) |
| |
FOR THE NINE MONTHS ENDED
MARCH 31, |
| REVENUES |
2009 |
2008 |
Product sales - net
|
$ 11,975 |
$ 8,940 |
Service and repair fees - net
|
6,936 |
7,444 |
Service and repair fees - related parties
- net
|
966 |
786 |
Management and other fees - net
|
5,518 |
6,354 |
Management and other
fees - related medical practices-net
|
2,181 |
2,739 |
License fees and royalties
|
1,755 |
1,158 |
| |
---------------- |
---------------- |
Total Revenues - Net
|
29,331 |
27,421 |
| |
---------------- |
---------------- |
| COSTS AND EXPENSES |
|
|
Costs related to product sales
|
7,590 |
8,566 |
Costs related to service and repair fees
|
2,696 |
3,546 |
Costs related to service and repair fees - related parties
|
376 |
375 |
Costs related to management and other fees
|
3,316 |
3,898 |
Costs related to management
and other fees - related medical practices
|
2,040 |
2,241 |
Research and development
|
2,681 |
3,675 |
Selling, general and administrative
|
9,955 |
15,544 |
Provision for bad debts
|
1,063 |
279 |
| |
---------------- |
---------------- |
Total Costs and Expenses
|
29,717 |
38,124 |
| |
---------------- |
---------------- |
| Loss From Operations |
( 386) |
(10,703) |
| |
|
|
| Interest Expense |
( 193) |
( 362) |
| Investment Income |
236 |
531 |
| Interest Income - Related Parties |
17 |
27 |
| Other (Expense) Income |
( 15) |
7 |
| Minority Interest in Income of Partnerships |
( 11) |
( 208) |
| Gain on Sale of Investment |
- |
571 |
| Gain on Sale of Consolidated Subsidiary |
1,448 |
3,395 |
| Provision for Income Taxes |
( 36) |
- |
| |
---------------- |
---------------- |
| NET INCOME (LOSS) |
$ 1,060 |
$ ( 6,742) |
| |
=========== |
=========== |
| Net Income (Loss) Available to Common Stockholders |
$ 997 |
$ (6,742) |
| |
=========== |
=========== |
| Basic Net Income (Loss) Per Common Share |
$ 0.20 |
$ (1.38) |
| |
=========== |
=========== |
| Diluted Net Income (Loss) Per Common Share |
$ 0.19 |
$ (1.38) |
| |
=========== |
=========== |
| Basic and Diluted Income per share - Common C |
$ 0.05 |
- |
| |
=========== |
=========== |
| Weighted Average Basic Common Shares Outstanding |
4,904,275 |
4,895,907 |
| |
=========== |
=========== |
| Weighted Average Diluted Common Shares Outstanding |
5,031,779 |
4,895,907 |
| |
=========== |
=========== |
UPRIGHT® and STAND-UP® are
registered trademarks and The Inventor of MR Scanning™,
Full Range of Motion™, pMRI™, Dynamic™, Multi-Position™,
True Flow™, The Proof is in the Picture™, Spondylography™ and
Spondylometry™ are trademarks of FONAR Corporation.
This release may include
forward-looking statements from the company that may or may
not materialize. Additional information
on factors that could potentially affect the company's financial
results may be found in the company's filings with the Securities
and Exchange Commission.
###
FONAR Corporation
110 Marcus Drive
Melville, N.Y. 11747
Tel. 631-694-2929
Fax. 631-390-9540
Email sales@FONAR.com
Investor Information

Site Map
| Terms of Use-Our
Privacy Policy Use
Copyright © 2009 FONAR- All Rights Reserved |